Dimethyltryptamine molecule:

Image from PubChem

DMT Clinical Trials

A Phase 1 Study to Determine the Pharmacokinetics and Pharmacodynamics of Single and Multiple Inhaled Doses of GH001 in Healthy Volunteers

To see complete record on clinicaltrials.gov, please visit this link

Id: NCT05163691

Organisation Name: GH Research Ireland Limited

Overal Status: Completed

Start Date: June 21, 2021

Last Update: December 20, 2021

Lead Sponsor: GH Research Ireland Limited

Brief Summary: The primary objective of this study is to investigate the serum pharmacokinetics of 5-MeO-DMT and its metabolite, bufotenine in healthy volunteers in a double-blind, placebo-controlled, randomized study design with single, inhaled doses of GH001 and in an open-label, non-randomized study design with intra-subject dose-escalation of GH001. As a secondary objective, the safety and tolerability of GH001, the mental health and well-being of the subjects after GH001 dosing(s), the pharmacodynamic profile of GH001 as evaluated by its psychoactive effects, and cognitive measures are also assessed.

  • Healthy Volunteers

Total execution time in seconds: 0.19764304161072